Ghent, Belgium, December 16 2019 – Today V-Bio Ventures announces its investment in Augustine Therapeutics, a new venture developing innovative therapeutics for patients suffering from Charcot-Marie-Tooth disease. A spin-off of VIB and KU Leuven, Augustine raises a seed-round of 4.2 million euro with V-Bio Ventures, PMV, Advent France Biotechnology, Gemma Frisius Fund and VIB.
More than 75 years after the initial discovery of lysergic acid diethylamide (LSD), psilocybin and other natural psychoactive drugs, and their initial exploitation by the western pharma industry, these substances have seen a recent revival in clinical research. Although banned in the notorious “War on Drugs” initiated by US President Nixon, the potential medicinal applications of these substances are finally being explored again, particularly for treating depressive disorders and other mental diseases. This article aims to shed light on a topic we highlighted before in this series - anti-science in biotech - to illustrate the consequences of research being abandoned, as well as the opportunities and additional challenges to making these substances finally available for patients in need.
Researchers studying a rare disease have identified a new gene responsible for human immune system regulation. An international collaboration combined information from both mouse models and a single human patient in an effort to find the underlying genetic cause of hemophagocytic syndrome. This discovery could potentially inspire a treatment for the deadly disease and provides new insights into the immune system.
PRESS RELEASE Amsterdam/Beerse, November 25, 2019 – Caelus Health, which develops food supplements and pharmaceutical products for the prevention, early treatment and management of cardio-metabolic diseases, is entering into a strategic collaboration with Nestlé Health Science (NHSc). The aim is to further develop and ultimately commercialize food supplements based on specific microbiota for the purpose of early intervention and nutritional management of diabetes and certain liver disorders.
The 2019 Nobel Prize in Physiology or Medicine was awarded to William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza. Their discoveries have paved the way for promising new strategies to fight anemia, cancer and many other diseases. We’re breaking down the research that led to the prize and why this work was so vital for modern medicine.
Ghent, Belgium, December 16 2019 – Today V-Bio Ventures announces its investment in Augustine Therapeutics, a new venture developing innovative therapeutics for patients suffering from Charcot-Marie-Tooth disease. A spin-off of VIB and KU Leuven, Augustine raises a seed-round of 4.2 million euro with V-Bio Ventures, PMV, Advent France Biotechnology, Gemma Frisius Fund and VIB.
More than 75 years after the initial discovery of lysergic acid diethylamide (LSD), psilocybin and other natural psychoactive drugs, and their initial exploitation by the western pharma industry, these substances have seen a recent revival in clinical research. Although banned in the notorious “War on Drugs” initiated by US President Nixon, the potential medicinal applications of these substances are finally being explored again, particularly for treating depressive disorders and other mental diseases. This article aims to shed light on a topic we highlighted before in this series - anti-science in biotech - to illustrate the consequences of research being abandoned, as well as the opportunities and additional challenges to making these substances finally available for patients in need.
Researchers studying a rare disease have identified a new gene responsible for human immune system regulation. An international collaboration combined information from both mouse models and a single human patient in an effort to find the underlying genetic cause of hemophagocytic syndrome. This discovery could potentially inspire a treatment for the deadly disease and provides new insights into the immune system.
PRESS RELEASE Amsterdam/Beerse, November 25, 2019 – Caelus Health, which develops food supplements and pharmaceutical products for the prevention, early treatment and management of cardio-metabolic diseases, is entering into a strategic collaboration with Nestlé Health Science (NHSc). The aim is to further develop and ultimately commercialize food supplements based on specific microbiota for the purpose of early intervention and nutritional management of diabetes and certain liver disorders.
The 2019 Nobel Prize in Physiology or Medicine was awarded to William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza. Their discoveries have paved the way for promising new strategies to fight anemia, cancer and many other diseases. We’re breaking down the research that led to the prize and why this work was so vital for modern medicine.